Documente Academic
Documente Profesional
Documente Cultură
Final report of the clinical trials of moist exposed burn ointment (MEBO): - a multiple center research
The Chinese Technical Center of Burns Wounds Surface ulcers (100053)
[Abstract] Objective: To further examine and evaluate the therapeutic effects and possible side effects of MEBO for varies of burns. Method: Five hundred and eight burn patients were observed in five burns centers, among which 363 patients were given MEBO treatment (treatment group) and 145 patients were give SD-Ag treatment (control group). There were no significant differences between the two groups in age, sex, wound cause, burns area, depth, sites, and wound severity. The observation index included: pattern of wound healing, analgetic effect, pain degree, complication on local and systemic, drug toxicity and side effects, etc. Results: The healing speed and quantity of different burns depth and burn wounds in the treatment group are significantly better than that of the control group. The characters of MEBO group are: rapid wound healing, low scar rate and disability, good analgetic effect, less pain and no toxicity and side effect. Conclusion: MEBO is an optimum drug suitable to treat all types of burns. [Key words] MEBO; SD-Ag treatment; Burns; Multi-center study In order to further examine and evaluate the therapeutic effects, main indications and possible side effects of BRT (MEBT/MEBO) in burn treatment, this multi-center study was designed to conduct MEBO phase III clinical trial. In this trial, MEBO was used for treating vast numbers of burn patients of both sexes and varied ages, all suffering burns from different causes, occurring at different sites, encompassing varied areas and penetrating to varied depths. The phase III trail was carried out at five branch centers of the China National Science and Technology Center for Burns, Wounds and Ulcers. These centers are the departments of five general hospitals located, respectively, in the cities of Changsha, Taishan, Dalian, Nanyang, China. The trail period spanned January. 1st, 1996 to June 30th, 1999. MATERIALS AND METHODS Clinical Data: General information Five hundred and eight hospitalized burn patients were observed. They were divided randomly into two groups: treatment group (MEBO group) and control group (silver sulfadiazine (SD-Ag) group). There were 363 patients in the treatment group, 282 males and 81 females (male: female = 3.5: 1), aged 10 days to 73 years (average 28.4 15.5 years), who were treated with MEBO. One hundred and forty-five patients were in the control group, 122 males and 23 females (male: female = 5.3: 1), aged 8 months to 72 years (average 29.2 12.1 years).
-1-
The Chinese Journal of Burns Wounds and Surface ulcers 2000, 12(2): 11-15